



Transforming the Treatment of Corneal & Ocular Surface Diseases

At Brightstar Therapeutics, we are redefining the standard of care for patients with corneal and ocular surface diseases.

We have developed an innovative corneal allograft that improves the condition of the ocular surface.



BrightMEM Corneal Allograft

Advanced Corneal Allograft Overcomes Limitations of Conventional Therapies

Using Brightstar Therapeutics' patented technology, we have developed novel corneal allografts that improve the conditions of the ocular surface to support the survival, maturation, and multiplication of corneal epithelial cells that can achieve the following benefits:

- Permanent basement membrane (type IV collagen) that promotes corneal epithelial adhesion and corneal re-epithelialization.
- Natural collagen structure of BrightMEM™ is the basis for a highly-durable tissue that provides protection against stromal degradation.
- Environment more conducive to limbal epithelial cell survival, growth, and proliferation compared to other therapeutic options.

About Us

Brightstar Therapeutics is a biotechnology company focused on providing innovative treatment options that improve clinical outcomes and quality of life for people living with corneal and ocular surface diseases.

Brightstar Therapeutics is the first company to offer a long-term solution for improving the surface of the ocular surface through its advanced corneal allograft, BrightMEM.

Team



Rajan Shukla
Chief Executive Officer



Rusty Kelly
Chief Operating Officer



Joseph Tauber, MD
Chief Medical Officer



Joshua Hou, MD
Chief Scientific Officer

Our Pipeline

Brightstar Therapeutics is committed to advancing novel, life-changing therapies.

Using our patented technology, we are developing a pipeline of cell therapy products.

PRODUCT

STAGE

STR 002 FOR LIMBAL
STEM CELL DEFICIENCY

PRE-CLINICAL

STR 003 FOR RETINAL
DISEASES

PRE-CLINICAL

CONTACT:



859.800.7147



info@brightstartx.com



www.brightstartx.com